tbuckley/cabot-search huggingface dataset:
Development of an Objective Structured Assessment of Technical Skills (OSATS) for Sclerotherapy
Authors: Melissa S Ma, Faraaz S Zafar, Mitchel P Goldman, Girish S Munavalli, Steven E Zimmet, Tri H Nguyen, Vineet Mishra, Todd V Cartee, Margaret Mann, Jeffrey T S Hsu, Sirunya Silapunt, Robert A Weiss, Margaret A Weiss, Misha Haq, Areeba Ahmed, Eric Koza, Victoria J Shi, Loma Dave, Michael Yi, Bianca Y Kang, Brian Cahn, Yoon Soo Cindy Bae, Lauren C S Kole, Daniel P Friedmann, Maggie L Chow, Kira Minkis, Markus Stücker, Cynthia A Schlick, Elika Hoss, Jenny C Hu, Nour Kibbi, Sami K Saikaly, Tanya Greywal, Deirdre Hooper, Neelam A Vashi, Alison Boucher, Kimberley H M Ward, Isaac M Neuhaus, Erica Ghareeb, Janiene Luke, Julie K Karen, Amanda Suggs, Jennifer Lucas, Ashley Decker, Joaquin C Brieva, Simon S Yoo, Kathleen Suozzi, Murad Alam
Journal: Journal of the American Academy of Dermatology (2024)
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Authors: Thomas Powles, James W.F. Catto, Matthew D. Galsky, Hikmat Al-Ahmadie, Joshua J. Meeks, Hiroyuki Nishiyama, Toan Quang Vu, Lorenzo Antonuzzo, Pawel Wiechno, Vagif Atduev, Ariel G. Kann, Tae-Hwan Kim, Cristina Suárez, Chao-Hsiang Chang, Florian Roghmann, Mustafa Özgüroğlu, Bernhard J. Eigl, Niara Oliveira, Tomas Buchler, Moran Gadot, Yousef Zakharia, Jon Armstrong, Ashok Gupta, Stephan Hois, Michiel S. van der Heijden
Journal: New England Journal of Medicine (2024)

Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve outcomes.
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
Authors: Arun A Azad, Mathias Bressel, Hsiang Tan, Mark Voskoboynik, Aneta Suder, Andrew J Weickhardt, Alexander Guminski, Roslyn J Francis, Javad Saghebi, Nattakorn Dhiantravan, Anthony M Joshua, Louise Emmett, Lisa Horvath, Declan G Murphy, Edward Hsiao, Bavanthi Balakrishnar, Peter Lin, Andrew Redfern, William Macdonald, Siobhan Ng, Sze-Ting Lee, David A Pattison, David Nadebaum, Ian D Kirkwood, Michael S Hofman
Journal: The Lancet Oncology (2024)
Subcutaneous versus intravenous nivolumab for renal cell carcinoma
Authors: L Albiges, M T Bourlon, M Chacón, H J Cutuli, Y A L Chuken, B Żurawski, J M Mota, I Magri, M Burotto, M Luz, J de Menezes, E P Y Ruiz, S Fu, M Richardet, B P Valderrama, M Maruzzo, S Bracarda, M Breckenridge, H E Vezina, D Rathod, Z Yu, Y Zhao, M Dixon, D Perumal, S George
Journal: Annals of Oncology (2024)
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase 3 KEYNOTE-006 study
Authors: G V Long, M S Carlino, C McNeil, A Ribas, C Gaudy-Marqueste, J Schachter, M Nyakas, D Kee, T M Petrella, A Blaustein, M Lotem, A M Arance, A I Daud, O Hamid, J Larkin, L Yao, R Singh, R Lal, C Robert
Journal: Annals of Oncology (2024)
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Authors: Michael J Morris, Daniel Castellano, Ken Herrmann, Johann S de Bono, Neal D Shore, Kim N Chi, Michael Crosby, Josep M Piulats, Aude Fléchon, Xiao X Wei, Hakim Mahammedi, Guilhem Roubaud, Hana Študentová, James Nagarajah, Begoña Mellado, Álvaro Montesa-Pino, Euloge Kpamegan, Samson Ghebremariam, Teri N Kreisl, Celine Wilke, Katja Lehnhoff, Oliver Sartor, Karim Fizazi
Journal: The Lancet (2024)
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Authors: Jedd D. Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, C. Lance Cowey, Dirk Schadendorf, John Wagstaff, Paola Queirolo, Reinhard Dummer, Marcus O. Butler, Andrew G. Hill, Michael A. Postow, Caroline Gaudy-Marqueste, Theresa Medina, Christopher D. Lao, John Walker, Iván Márquez-Rodas, John B.A.G. Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S. Carlino, Shahneen Sandhu, Céleste Lebbé, Paolo A. Ascierto, Georgina V. Long, Corey Ritchings, Ayman Nassar, Margarita Askelson, Melanie Pe Benito, Wenjia Wang, F. Stephen Hodi, James Larkin
Journal: New England Journal of Medicine (2024)

Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given that patients with advanced melanoma are living longer than 7.5 years, longer-term data were needed to address new clinically relevant questions.
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
Authors: Peter G M de Gooyer, Yara L Verschoor, Lauren D W van den Dungen, Sara Balduzzi, Hendrik A Marsman, Marnix H Geukes Foppen, Cecile Grootscholten, Simone Dokter, Anne G den Hartog, Wieke H M Verbeek, Karlijn Woensdregt, Joris J van den Broek, Steven J Oosterling, Ton N Schumacher, Koert F D Kuhlmann, Regina G H Beets-Tan, John B A G Haanen, Monique E van Leerdam, Jose G van den Berg, Myriam Chalabi
Journal: Nature Medicine (2024)
A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4 trimethylation of the Rac1 promoter
Authors: Qian Ding, Jianghong Cai, Li Jin, Wei Hu, Wu Song, Peter Rose, Zhiyuan Tang, Yangyang Zhan, Leilei Bao, Wei Lei, Yi Zhun Zhu
Journal: MedComm (2024)

SMYD3 (SET and MYND domain-containing 3) is a histone lysine methyltransferase highly expressed in different types of cancer(s) and is a promising epigenetic target for developing novel antitumor therapeutics. No selective inhibitors for this protein have been developed for cancer treatment. Therefore, the current study describes developing and characterizing a novel small molecule ZYZ384 screened and synthesized based on SMYD3 structure. Virtual screening was initially used to identify a lead compound and followed up by modification to get the novel molecules. Several technologies were used to facilitate compound screening about these novel molecules' binding affinities and inhibition activities with SMYD3 protein; the antitumor activity has been assessed in vitro using various cancer cell lines. In addition, a tumor-bearing nude mice model was established, and the activity of the selected molecule was determined in vivo. Both RNA-seq and chip-seq were performed to explore the antitumor mechanism. This work identified a novel small molecule ZYZ384 targeting SMYD3 with antitumor activity and impaired hepatocellular carcinoma tumor growth by reducing H3K4 trimethylation of the Rac1 promoter triggering the tumor cell cycle arrest through the AKT pathway.
The interaction of innate immune and adaptive immune system
Authors: Ruyuan Wang, Caini Lan, Kamel Benlagha, Niels Olsen Saraiva Camara, Heather Miller, Masato Kubo, Steffen Heegaard, Pamela Lee, Lu Yang, Huamei Forsman, Xingrui Li, Zhimin Zhai, Chaohong Liu
Journal: MedComm (2024)

The innate immune system serves as the body's first line of defense, utilizing pattern recognition receptors like Toll-like receptors to detect pathogens and initiate rapid response mechanisms. Following this initial response, adaptive immunity provides highly specific and sustained killing of pathogens via B cells, T cells, and antibodies. Traditionally, it has been assumed that innate immunity activates adaptive immunity; however, recent studies have revealed more complex interactions. This review provides a detailed dissection of the composition and function of the innate and adaptive immune systems, emphasizing their synergistic roles in physiological and pathological contexts, providing new insights into the link between these two forms of immunity. Precise regulation of both immune systems at the same time is more beneficial in the fight against immune-related diseases, for example, the cGAS-STING pathway has been found to play an important role in infections and cancers. In addition, this paper summarizes the challenges and future directions in the field of immunity, including the latest single-cell sequencing technologies, CAR-T cell therapy, and immune checkpoint inhibitors. By summarizing these developments, this review aims to enhance our understanding of the complexity interactions between innate and adaptive immunity and provides new perspectives in understanding the immune system.
Accelerated Longitudinal Glycemic Changes in Relation to Urinary Toxic/Essential Metals and Metal Mixtures Among Mexican Americans Living in Starr County, Texas
Authors: Margaret C. Weiss, Jiehuan Sun, Brian P. Jackson, Mary E. Turyk, Luyu Wang, Eric L. Brown, David Aguilar, Sharon A. Brown, Craig L. Hanis, Maria Argos, Robert M. Sargis
Journal: Diabetes Care (2024)

Metal and metalloid exposures (hereafter "metals") are associated with adverse health outcomes, including type 2 diabetes; however, previous studies were largely cross- sectional or underpowered. Furthermore, underserved racial/ethnic groups are underrepresented in environmental health research despite having higher rates of type 2 diabetes and a greater risk of metal exposures. Consequently, we evaluated continuous glycemic traits in relation to baseline urinary toxic metal, essential metal, and metal mixtures in a cohort of Mexican American adults.
Patient‐reported outcome and survival in premenopausal hormone receptor‐positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real‐world study
Authors: Yaping Yang, Fengxia Gan, Ting Luo, Qun Lin, Wenqian Yang, Lili Chen, Wei Zhang, Qiang Liu, Chang Gong
Journal: MedComm (2024)

Toremifene, a selective estrogen receptor modulator, is commonly used in China for premenopausal breast cancer patients. This real-world study aimed to compare patient-reported outcome (PRO) and survival between toremifene and aromatase inhibitor (AI) plus ovarian function suppression (OFS) in patients with moderate-/high-risk premenopausal hormone receptor (HR)-positive breast cancer. The primary endpoint was PROs, assessed using SF-36 and EQ-5D-5L questionnaires between January and March 2023. A total of 392 patients were included, with 171 receiving toremifene and 221 receiving AI. The toremifene group showed significantly higher scores in the role physical (
Anoikis in cell fate, physiopathology, and therapeutic interventions
Authors: Jie Mei, Xue‐Yao Jiang, Hui‐Xiang Tian, Ding‐Chao Rong, Jia‐Nan Song, Luozixian Wang, Yuan‐Shen Chen, Raymond C. B. Wong, Cheng‐Xian Guo, Lian‐Sheng Wang, Lei‐Yun Wang, Peng‐Yuan Wang, Ji‐Ye Yin
Journal: MedComm (2024)

The extracellular matrix (ECM) governs a wide spectrum of cellular fate processes, with a particular emphasis on anoikis, an integrin-dependent form of cell death. Currently, anoikis is defined as an intrinsic apoptosis. In contrast to traditional apoptosis and necroptosis, integrin correlates ECM signaling with intracellular signaling cascades, describing the full process of anoikis. However, anoikis is frequently overlooked in physiological and pathological processes as well as traditional in vitro research models. In this review, we summarized the role of anoikis in physiological and pathological processes, spanning embryonic development, organ development, tissue repair, inflammatory responses, cardiovascular diseases, tumor metastasis, and so on. Similarly, in the realm of stem cell research focused on the functional evolution of cells, anoikis offers a potential solution to various challenges, including in vitro cell culture models, stem cell therapy, cell transplantation, and engineering applications, which are largely based on the regulation of cell fate by anoikis. More importantly, the regulatory mechanisms of anoikis based on molecular processes and ECM signaling will provide new strategies for therapeutic interventions (drug therapy and cell-based therapy) in disease. In summary, this review provides a systematic elaboration of anoikis, thus shedding light on its future research.
Improving education in psychiatry in an evolving scenario: the activities of the <scp>WPA</scp> Section on Education in Psychiatry
Authors: Gaia Sampogna, Hasanen Al‐Taiar, Franziska Baessler, Bulent Coskun, Hussien Elkholy, Mariana Pinto da Costa, Rodrigo Ramalho, Andrea Fiorillo
Journal: World Psychiatry (2024)
Where do neurodevelopmental conditions fit in transdiagnostic psychiatric frameworks? Incorporating a new neurodevelopmental spectrum
Authors: Giorgia Michelini, Christina O. Carlisi, Nicholas R. Eaton, Jed T. Elison, John D. Haltigan, Roman Kotov, Robert F. Krueger, Robert D. Latzman, James J. Li, Holly F. Levin‐Aspenson, Giovanni A. Salum, Susan C. South, Kasey Stanton, Irwin D. Waldman, Sylia Wilson
Journal: World Psychiatry (2024)

Features of autism spectrum disorder, attention‐deficit/hyperactivity disorder, learning disorders, intellectual disabilities, and communication and motor disorders usually emerge early in life and are associated with atypical neurodevelopment. These “neurodevelopmental conditions” are grouped together in the DSM‐5 and ICD‐11 to reflect their shared characteristics. Yet, reliance on categorical diagnoses poses significant challenges in both research and clinical settings (e.g., high co‐occurrence, arbitrary diagnostic boundaries, high within‐disorder heterogeneity). Taking a transdiagnostic dimensional approach provides a useful alternative for addressing these limitations, accounting for shared underpinnings across neurodevelopmental conditions, and characterizing their common co‐occurrence and developmental continuity with other psychiatric conditions. Neurodevelopmental features have not been adequately considered in transdiagnostic psychiatric frameworks, although this would have fundamental implications for research and clinical practices. Growing evidence from studies on the structure of neurodevelopmental and other psychiatric conditions indicates that features of neurodevelopmental conditions cluster together, delineating a “neurodevelopmental spectrum” ranging from normative to impairing profiles. Studies on shared genetic underpinnings, overlapping cognitive and neural profiles, and similar developmental course and efficacy of support/treatment strategies indicate the validity of this neurodevelopmental spectrum. Further, characterizing this spectrum alongside other psychiatric dimensions has clinical utility, as it provides a fuller view of an individual's needs and strengths, and greater prognostic utility than diagnostic categories. Based on this compelling body of evidence, we argue that incorporating a new neurodevelopmental spectrum into transdiagnostic frameworks has considerable potential for transforming our understanding, classification, assessment, and clinical practices around neurodevelopmental and other psychiatric conditions.
Orbicular‐Donor–Acceptor System in N‐doped Nanographene for Highly Efficient NIR‐II Photothermal Therapy
Authors: Chengyan Zhao, Chulin Qu, Yingzhe Hu, Fan Wu, Shaohai Liu, Fangjian Cai, Yuhang Chen, Yudong Qiu, Zhen Shen
Journal: Advanced Healthcare Materials (2024)

Abstract Developing stable and efficient photothermal agents (PTAs) for the second near‐infrared window (NIR‐II, 1 000–1700 nm) photothermal therapy (PTT) is highly desirable but remains challenging. Herein, a facile strategy to prepare NIR‐II nano‐PTA based on the ionic N‐doped nanographene hexapyrrolohexaazacoronene (HPHAC) is reported featuring a specific orbicular‐donor–acceptor (O‐D–A) structure. Oxidizing HPHAC 1 to dication 1 2+ causes a substantial decrease in its band gap, leading to a shift in absorption from the confined UV region to a broad absorption range that reaches up to 1400 nm. The dication 1 2+ exhibits global aromaticity and excellent stability. Theoretical investigation demonstrates that the strong NIR‐II absorption of 1 2+ is attributed to a distinct inner‐to‐outer intramolecular charge transfer. Encapsulating 1 2+ with amphiphilic polymers results in water‐soluble 1 2+ NPs with retained optical characteristics. The 1 2+ NPs exhibit exceptional biocompatibility, intense photoacoustic responses, and a high photothermal conversion efficiency of 72% under the 1064 nm laser irradiation, enabling efficient PTT of cancer cells. The “O‐D–A” system on HPHAC, which is created by a simple redox approach, provides a novel strategy to construct efficient NIR‐II photothermal materials through molecular engineering of nanographenes.
Albumin-based co-loaded sonosensitizer and STING agonist nanodelivery system for enhanced sonodynamic and immune combination antitumor therapy
Authors: Huaping Huang, Lihua Du, Rishun Su, Zhuoyuan Li, Yu Shao, Yeling Yuan, Chen Wang, Changzheng Lu, Yulong He, Haozhe He, Changhua Zhang
Journal: Journal of Controlled Release (2024)
Associations between physical diseases and subsequent mental disorders: a longitudinal study in a population‐based cohort
Authors: Natalie C. Momen, Søren Dinesen Østergaard, Uffe Heide‐Jorgensen, Henrik Toft Sørensen, John J. McGrath, Oleguer Plana‐Ripoll
Journal: World Psychiatry (2024)

People with physical diseases are reported to be at elevated risk of subsequent mental disorders. However, previous studies have considered only a few pairs of conditions, or have reported only relative risks. This study aimed to systematically explore the associations between physical diseases and subsequent mental disorders. It examined a population‐based cohort of 7,673,978 people living in Denmark between 2000 and 2021, and followed them for a total of 119.3 million person‐years. The study assessed nine broad categories of physical diseases (cardiovascular, endocrine, respiratory, gastrointestinal, urogenital, musculoskeletal, hematological and neurological diseases, and cancers), encompassing 31 specific diseases, and the subsequent risk of mental disorder diagnoses, encompassing the ten ICD‐10 groupings (organic, including symptomatic, mental disorders; mental disorders due to psychoactive substance use; schizophrenia and related disorders; mood disorders; neurotic, stress‐related and somatoform disorders; eating disorders; personality disorders; intellectual disabilities; pervasive developmental disorders; and behavioral and emotional disorders with onset usually occurring in childhood and adolescence). Using Poisson regression, the overall and time‐dependent incidence rate ratios (IRRs) for pairs of physical diseases and mental disorders were calculated, adjusting for age, sex and calendar time. Absolute risks were estimated with the Aalen‐Johansen estimator. In total, 646,171 people (8.4%) were identified as having any mental disorder during follow‐up. All physical diseases except cancers were associated with an elevated risk of any mental disorder. For the nine broad pairs of physical diseases and mental disorders, the median point estimate of IRR was 1.51 (range: 0.99‐1.84; interquartile range: 1.29‐1.59). The IRRs ranged from 0.99 (95% CI: 0.98‐1.01) after cancers to 1.84 (95% CI: 1.83‐1.85) after musculoskeletal diseases. Risks varied over time after the diagnosis of physical diseases. The cumulative mental disorder incidence within 15 years after diagnosis of a physical disease varied from 3.73% (95% CI: 3.67‐3.80) for cancers to 10.19% (95% CI: 10.13‐10.25) for respiratory diseases. These data document that most physical diseases are associated with an elevated risk of subsequent mental disorders. Clinicians treating physical diseases should constantly be alert to the possible development of secondary mental disorders.
“Periodontal ligament‐on‐chip” as a Novel Tool for Studies on the Physiology and Pathology of Periodontal Tissues
Authors: Sara Svanberg, Elisabeth Hirth, Thimios A. Mitsiadis, Petra S. Dittrich
Journal: Advanced Healthcare Materials (2024)

Abstract Teeth exert fundamental physiological functions, such as mastication and speech, and are a key feature of oral health that affects life quality. Teeth are anchored to the alveolar bone via the periodontal ligament, which provides stability to the teeth and absorbs mechanical stresses during mastication. Periodontal infection leads to periodontitis, a severe inflammation of the supporting soft tissues that ultimately cause tooth loss. Despite the pressing need of periodontal regeneration for improved oral care, efficient in vitro models of the periodontal tissues are still missing, thus hampering the development of novel, faster, and more effective therapy modalities. Herein, a novel “periodontal ligament (PDL)‐on‐chip” model that integrates patient‐derived periodontal ligament cells (PDLCs) and endothelial cells is introduced. This microfluidic platform provides optimal conditions for the formation of extensive and perfusable vascular networks. Furthermore, PDLCs elicit blood vessels’ development and maturation while establishing close contacts with the endothelial cells. Potential applications for inflammatory periodontal diseases are also successfully displayed in the “PDL‐on‐chip” by stimulating inflammation and detecting inflammatory cytokines. This work offers a cornerstone for more complex and specialized microfluidic dental models, which are necessary to unravel complex oral diseases that affect individuals’ general health that go beyond the field of dentistry.
From Inception to Malignancy: the Co-evolution of Pancreatic Cancer and Its Immunosuppressive Microenvironment
Authors: Filip Bednar, Lee Y. Olsen, Marina Pasca di Magliano
Journal: Cancer Research (2024)

Abstract Published in Cancer Research in 2007, Clark and colleagues first introduced the concept that the immune microenvironment evolves in lockstep with the progression of pancreatic cancer. Leveraging genetically engineered mouse models of the disease that were described a few years earlier, Clark and colleagues used a combination of approaches to describe the dynamics of immune evolution in precursor lesions all the way to overt malignancy. They discovered that immunosuppression is established at the earliest stages of carcinogenesis. Here, we discuss their findings, how they led to a wealth of functional work, and how they have been expanded upon since the advent of -omics technologies. See related article by Clark and colleagues, Cancer Res 2007;67:9518–27